Latest Conference Coverage

Epigenetic Age Acceleration Shows Association With Secondary Progressive Multiple Sclerosis

New findings from a study presented at the 2024 ACTRIMS Forum revealed an increase in epigenetic age acceleration among a subgroup of patients with multiple sclerosis.

Individual and Group Level Cognitive Benefits of Cladribine Displayed in MAGNIFY-MS Study

Using a 4-point score change on Symbol Digits Modalities Test, more than 80% of patients had either sustained improvement or no sustained change after 2 years of treatment with cladribine.

Glatiramer Acetate Depot Demonstrates Sustained Long-Term Safety Profile as Potential MS Therapy

GA Depot, which remains under review by the FDA, showed a safe and tolerable profile in an additional 52-week extension period.

Ozanimod's Consistent Efficacy in Long-Term Treatment for Multiple Sclerosis: Jeffrey Cohen, MD

The director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research talked about recent findings on long-term impact of ozanimod in patients with relapsing-remitting multiple sclerosis presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

Preclinical Data Shows NLRX1 Protects Against Neurodegeneration in Multiple Sclerosis

A new study showed that NLRX1, a mitochondrial innate immune sensor, may serve as a promising therapeutic target to prevent inflammatory neurodegeneration in multiple sclerosis.

Challenges for the Neuromuscular Community Entering Treatment Era: Barry Byrne, MD, PhD

The chief medical advisor at the Muscular Dystrophy Association provided perspective on the upcoming meeting and the conversations surrounding new therapeutics for diseases that once had little to nothing. [WATCH TIME: 4 minutes]

Obesity Accelerates Disease Progression in Patients With Multiple Sclerosis

A recent study presented at 2024 ACTRIMS Forum showed that body mass index may influence disease progression in patients with multiple sclerosis.

Neurofilament Light Levels Predict Future MS Disease Activity Regardless of Race or Ethnicity

These data, presented at 2024 ACTRIMS Forum, highlight the impacts neurofilament light has on patients with multiple sclerosis irrespective of race or ethnicity.

Phase 3 DAYBREAK Trial Highlights Long-Term Efficacy of Ozanimod for Relapsing Multiple Sclerosis

Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.

Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

Efficacy of Adjunctive Therapies for Acute Ischemic Stroke Based on Phase 3 MOST Trial: Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MS

The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]

Cost-Effective Detection of Poststroke Atrial Fibrillation Identified in STROKE-AF Trial: David Z. Rose, MD

The professor of neurology at University of South Florida talked about the cost-effectiveness of insertable cardiac monitors to detect new atrial fibrillation in patients with large-artery or small-vessel disease stroke. [WATCH TIME: 4 minutes]

Future Role of Neurofilament Light in ALS Drug Development, Clinical Trials: Rita Sattler, PhD, MSc

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided perspective on the approval of tofersen (Qalsody; Biogen) for patients with ALS and the ways neurofilament light will be used going forward. [WATCH TIME: 3 minutes]

Antiplatelets Versus Anticoagulation For the Treatment of Cervical Artery Dissection: Shadi Yaghi, MD

The associate professor of neurology at Brown University talked about findings from an observational study investigating treatment options antiplatelets and anticoagulation for cervical artery dissection. [WATCH TIME: 8 minutes]

Lessons Learned From Cleveland Clinic’s Mobile Stroke Unit: Blake Buletko, MD

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on the biggest learning experiences over the past decade for Cleveland Clinic’s mobile stroke unit. [WATCH TIME: 4 minutes]

Assessing In-Hospital Stroke Risk in Pregnant Patients Using Assisted Reproductive Technologies: Ava L. Liberman, MD

The medical director of the Stroke Center at Weill Cornell Medicine talked about results from a recent study on the risk of stroke in patients on assisted reproductive technologies during delivery hospitalization. [WATCH TIME: 4 minutes]

NeuroVoices: Rita Sattler, MD, MSc, on 2024 MDA Conference and Advances in ALS Research

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.

Potential of Mobile Stroke Units to Acutely Treat Intracerebral Hemorrhage: Blake Buletko, MD

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on a recently conducted study showing the benefits of timely treatment through mobile stroke units for patients with acute intracerebral hemorrhage. [WATCH TIME: 6 minutes]

Safely Expanding the Time Window of Thrombolysis: Gregory W. Albers, MD

The Emergence of Novel Biomarkers and Model Systems for ALS: Rita Sattler, MD, MSc

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided comments on her session track at the upcoming 2024 MDA conference and some of the recent advancements in ALS research. [WATCH TIME: 4 minutes]

Highlights of ISC 2024, Trials and Future Innovations for Stroke Care: Tudor Jovin, MD; Lauren Sansing, MD, MS, FAHA

The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]

Head-of-Bed Positioning Impact on Patients' Recovery Following Thrombectomy: Anne W. Alexandrov PhD, RN, CCRN, ANVP-BC, NVRN-BC, FAAN

The professor of nursing and neurology at the University of Tennessee Health Science Center talked about findings from a study investigating head-of-bed position in patients undergoing thrombectomy which was presented at ISC 2024. [WATCH TIME: 6 minutes]

Understanding Patient Subgroups Who Benefit From Tenecteplase After 4.5 Hours: Gregory W. Albers, MD

The professor of neurology and director of the Stanford Stroke Center provided commentary on clinical implications of findings from the TIMELESS trial assessing tenecteplase initiated in the late window after stroke onset. [WATCH TIME: 4 minutes]

Using a Portable Low Field MRI for Timely Diagnoses of Stroke: Annabel Sorby-Adams, PhD

The postdoctoral research fellow in neurology at Harvard Medical School talked about the potential of a portable low field MRI device to provide timely and cost-effective diagnoses for stroke. [WATCH TIME: 4 minutes]

Next Steps Following EMBOLISE Trial and Addressing Unmet Needs for Subdural Hematomas: Jason M. Davies, MD, PhD

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo discussed the questions that still remain following the EMBOLISE trial and the use of embolization in the treatment of subacute and subdural hematoma. [WATCH TIME: 5 minutes]

Assisted Reproductive Technologies Increase Risk of In-Hospital Stroke in Pregnant Women

In a recent study presented at ISC 2024, results revealed that patients who used assisted reproductive technologies therapy during hospitalization for delivery had a higher risk of stroke than those who did not use such therapies.

Anticoagulation Reduces Risk of Stroke in Cervical Artery Dissection, With Effects Based on Timing

A recent study showed anticoagulation reduced ischemic stroke risk in patients with cervical artery dissection; however, cautioned is warned about the importance of transitioning to antiplatelet therapy at a certain point.

Anti-Inflammatory Agent RNS60 Demonstrates Robust Impact on Poststroke Disability in Phase 2 RESCUE Study

Topline results from the RESCUE trial indicate that RNS60, an anti-inflammatory agent, demonstrates safety and potential efficacy in acute ischemic stroke.

TIMELESS Trial Reveals Tenecteplase Safe in Late Window, With Efficacy in Subgroups of M1 Occlusion

Insights on the EMBOLISE Trial and Advancing Treatment for Subdural Hematoma: Jason M. Davies, MD, PhD

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo provided commentary on the significant findings from the EMBOLISE trial presented at the 2024 International Stroke Conference. [WATCH TIME: 4 minutes]